1. Thrombolytic Therapy in Acute Myocardial Infarction

   • Sol Sherry

   Section 1: Introduction to Thrombolysis in Acute Myocardial Infarction 18 October 2012 Pages: 1 - 12

2. Physiological Balance of Haemostasis and Bleeding

   • Victor J. Marder
   • Charles W. Francis

   Section 1: Introduction to Thrombolysis in Acute Myocardial Infarction 18 October 2012 Pages: 13 - 21

3. Recent Clinical Developments in Thrombolysis in Acute Myocardial Infarction

   • Jeffrey L. Anderson

   Section 1: Introduction to Thrombolysis in Acute Myocardial Infarction 18 October 2012 Pages: 22 - 32

4. Preclinical Pharmacological Evaluation of Anisoylated Plasminogen Streptokinase Activator Complex

   • H. Ferres

   Section 1: Introduction to Thrombolysis in Acute Myocardial Infarction 18 October 2012 Pages: 33 - 50

5. Evidence for the Progressive Uptake of Anisoylated Plasminogen Streptokinase Activator Complex by Clots in Human Plasma in Vitro

   • R. Fears
   • H. Ferres
   • R. Standring

   Short Communication 18 October 2012 Pages: 51 - 56

6. The Protective Effect of Acylation on the Stability of Anisoylated Plasminogen Streptokinase Activator Complex in Human Plasma

   • R. Fears
   • H. Ferres
   • R. Standring

   Short Communication 18 October 2012 Pages: 57 - 63

7. Consequences of Antibody Binding in Vitro on the Pharmacological Properties of Anisoylated Plasminogen Streptokinase Activator Complex

   • R. Fears
   • H. Ferres
   • R. Standring

   Short Communication 18 October 2012 Pages: 64 - 68

8. The Effect of Heparin and Fibrin on the Enzymatic Efficiencies of Thrombolytics in Vitro

   • R. Fears

   Short Communication 18 October 2012 Pages: 69 - 74

9. Non-Exchange of Streptokinase from Anisoylated Plasminogen Streptokinase Activator Complex and Other Acylated Streptokinase-Plasminogen Complexes

   • Richard A. G. Smith

   Short Communication 18 October 2012 Pages: 75 - 79

10. Deacylation Studies in Vitro on Anisoylated Plasminogen Streptokinase Activator Complex

    • H. Ferres
    • M. Hibbs
    • R. A. G. Smith

    Short Communication 18 October 2012 Pages: 80 - 82

11. Evidence for a Sustained Fibrinolytic Response to Anisoylated Plasminogen Streptokinase Activator Complex in Vitro

    • R. Fears

    Short Communication 18 October 2012 Pages: 83 - 87

12. Pharmacokinetic Properties of Anisoylated Plasminogen Streptokinase Activator Complex and Other Thrombolytic Agents in Animals and in Humans

    • B. Nunn
    • A. Esmail
    • R. Standring

    Short Communication 18 October 2012 Pages: 88 - 92

13. Fibrin Binding

    • C. J. Banton
    • B. G. Overell

    Section 1: Introduction to Thrombolysis in Acute Myocardial Infarction 18 October 2012 Pages: 93 - 96

14. The Preclinical Toxicology of Anisoylated Plasminogen Streptokinase Activator Complex

    • J. A. Artus
    • A. Cockburn
    • D. J. White

    Section 1: Introduction to Thrombolysis in Acute Myocardial Infarction 18 October 2012 Pages: 97 - 101

15. Discussion Section 1

    • K. R. L. Mansford
    • S. Sherry

    Section 1: Introduction to Thrombolysis in Acute Myocardial Infarction 18 October 2012 Pages: 102 - 103

16. Summary of Early Clinical Experience with Anisoylated Plasminogen Streptokinase Activator Complex in the Treatment of Acute Myocardial Infarction

    • D. Jackson

    Section 2: Efficacy of Anisoylated Plasminogen Streptokinase Activator Complex: Evidence of Vessel Patency 18 October 2012 Pages: 104 - 111

17. Early Clinical Evaluation of the Intravenous Treatment of Acute Myocardial Infarction with Anisoylated Plasminogen Streptokinase Activator Complex

    • W. Kasper
    • Th. Meinertz
    • H. Just

    Section 2: Efficacy of Anisoylated Plasminogen Streptokinase Activator Complex: Evidence of Vessel Patency 18 October 2012 Pages: 112 - 116

18. Achievement of Coronary Artery Patency by Use of Anisoylated Plasminogen Streptokinase Activator Complex in Acute Myocardial Infarction

    • W. S. Hillis
    • R. S. Hornung
    • F. G. Dunn

    Section 2: Efficacy of Anisoylated Plasminogen Streptokinase Activator Complex: Evidence of Vessel Patency 18 October 2012 Pages: 117 - 123

19. Dose-Ranging Studies of Anisoylated Plasminogen Streptokinase Activator Complex

    • Victor J. Marder
    • Robert L. Rothbard
    • Elliot C. Norry

    Section 2: Efficacy of Anisoylated Plasminogen Streptokinase Activator Complex: Evidence of Vessel Patency 18 October 2012 Pages: 124 - 132

20. A Randomised Placebo-Controlled Pilot Dose-Response Study with Anisoylated Plasminogen Streptokinase Activator Complex in Acute Coronary Artery Occlusions

    • A. Leizorovicz
    • G. Durrieu
    • J.-P. Boissel

    Section 2: Efficacy of Anisoylated Plasminogen Streptokinase Activator Complex: Evidence of Vessel Patency 18 October 2012 Pages: 133 - 137

21. A Placebo-Controlled Patency Study of Intravenous Anisoylated Plasminogen Streptokinase Activator Complex 30U in Acute Myocardial Infarction

    • D. P. de Bono

    Short Communication 18 October 2012 Pages: 138 - 139

22. Intravenous Anisoylated Plasminogen Streptokinase Activator Complex versus Intravenous Streptokinase in Evolving Myocardial Infarction

    • M. L. Brochier
    • L. Quilliet
    • J. P. Favier

    Section 2: Efficacy of Anisoylated Plasminogen Streptokinase Activator Complex: Evidence of Vessel Patency 18 October 2012 Pages: 140 - 145

23. An Interim Report of A Double-Blind Placebo-Controlled Recanalisation Study of Anisoylated Plasminogen Streptokinase Activator Complex in Acute Myocardial Infarction

    • Adam D. Timmis
    • Brian Griffin
    • Edgar Sowton

    Section 2: Efficacy of Anisoylated Plasminogen Streptokinase Activator Complex: Evidence of Vessel Patency 18 October 2012 Pages: 146 - 150

24. Comparison of Intravenous Anisoylated Plasminogen Streptokinase Activator Complex with Intracoronary Streptokinase in Acute Myocardial Infarction

    • J. J. R. M. Bonnier

    Section 2: Efficacy of Anisoylated Plasminogen Streptokinase Activator Complex: Evidence of Vessel Patency 18 October 2012 Pages: 151 - 153

25. Reperfusion in Acute Myocardial Infarction

    • Jeffrey L. Anderson

    Section 2: Efficacy of Anisoylated Plasminogen Streptokinase Activator Complex: Evidence of Vessel Patency 18 October 2012 Pages: 154 - 162

26. Acute Coronary Occlusion and Reperfusion

    • S. G. Sorensen
    • R. A. Hackworthy
    • J. L. Anderson

    Section 2: Efficacy of Anisoylated Plasminogen Streptokinase Activator Complex: Evidence of Vessel Patency 18 October 2012 Pages: 163 - 168

27. Evaluation of 2 Intravenous Thrombolytic Agents (Anisoylated Plasminogen Streptokinase Activator Complex versus Streptokinase) in Patients with Acute Myocardial Infarction

    • R. Seabra-Gomes
    • J. Aniceto Silva
    • F. Crespo

    Section 2: Efficacy of Anisoylated Plasminogen Streptokinase Activator Complex: Evidence of Vessel Patency 18 October 2012 Pages: 169 - 174

28. Anisoylated Plasminogen Streptokinase Activator Complex versus Streptokinase in Acute Myocardial Infarction

    • P. Monnier
    • U. Sigwart
    • L. Kappenberger

    Section 2: Efficacy of Anisoylated Plasminogen Streptokinase Activator Complex: Evidence of Vessel Patency 18 October 2012 Pages: 175 - 178

29. Intracoronary Streptokinase versus Intravenous Anisoylated Plasminogen Streptokinase Activator Complex in the Treatment of Acute Myocardial Infarction

    • Ludwig Kaspar
    • Ronald Karnik
    • Jörg Slany

    Section 2: Efficacy of Anisoylated Plasminogen Streptokinase Activator Complex: Evidence of Vessel Patency 18 October 2012 Pages: 179 - 182

30. Intravenous Bolus Application of Streptokinase and of Anisoylated Plasminogen Streptokinase Activator Complex in Acute Myocardial Infarction

    • P. Hellstern
    • P. Doenecke
    • E. Wenzel

    Short Communication 18 October 2012 Pages: 183 - 185

31. Evaluation of the Efficacy and Safety of Anisoylated Plasminogen Streptokinase Activator Complex in Early Myocardial Infarction

    • S. J. Lenhoff
    • A. R. Horak
    • P. J. Commerford

    Short Communication 18 October 2012 Pages: 186 - 188

32. Discussion: Section 2

    • J. Anderson
    • L. Bossaert

    Section 2: Efficacy of Anisoylated Plasminogen Streptokinase Activator Complex: Evidence of Vessel Patency 18 October 2012 Pages: 189 - 190

33. Left Ventricular Function after Anisoylated Plasminogen Streptokinase Activator Complex

    • M. Been
    • A. L. Muir
    • D. P. de Bono

    Section 3: Efficacy of Anisoylated Plasminogen Streptokinase Activator Complex: Evidence of Myocardial Function and Mortality Benefit 18 October 2012 Pages: 191 - 197

34. Electrocardiographic and Enzymatic Infarct Size in a Randomised Study of Intracoronary Streptokinase and Intravenous Anisoylated Plasminogen Streptokinase Activator Complex in Acute Myocardial Infarction

    • R. A. Hackworthy
    • S. G. Sorensen
    • J. L. Anderson

    Section 3: Efficacy of Anisoylated Plasminogen Streptokinase Activator Complex: Evidence of Myocardial Function and Mortality Benefit 18 October 2012 Pages: 198 - 208

35. The Effect of Thrombolytic Therapy with Anisoylated Plasminogen Streptokinase Activator Complex on the Indicators of Myocardial Salvage

    • M. B. Buchalter
    • J. P. Bourke
    • D. S. Reid

    Section 3: Efficacy of Anisoylated Plasminogen Streptokinase Activator Complex: Evidence of Myocardial Function and Mortality Benefit 18 October 2012 Pages: 209 - 215

36. Assessment of Left Ventricular Function in a Randomised Study of Intravenous Anisoylated Plasminogen Streptokinase Activator Complex versus Heparin in Acute Myocardial Infarction

    • Y. Taeymans
    • P. Materne

    Section 3: Efficacy of Anisoylated Plasminogen Streptokinase Activator Complex: Evidence of Myocardial Function and Mortality Benefit 18 October 2012 Pages: 216 - 220

37. Treatment of Acute Myocardial Infarction with Anisoylated Plasminogen Streptokinase Activator Complex in a District Hospital

    • D. A. Chamberlain

    Short Communication 18 October 2012 Pages: 221 - 222

38. Randomised Multicentre Trial of Anisoylated Plasminogen Streptokinase Activator Complex versus Heparin

    • Th. Meinertz
    • W. Kasper

    Short Communication 18 October 2012 Pages: 223 - 226

39. AIMS

    • UK APSAC Advisory Committee
    • D. G. Julian

    Short Communication 18 October 2012 Pages: 227 - 228

40. Should We Intervene Following Thrombolytic Therapy?

    • UK APSAC Advisory Committee
    • D. G. Julian

    Short Communication 18 October 2012 Pages: 229 - 230

41. Prehospital Administration of Anisoylated Plasminogen Streptokinase Activator Complex in Acute Myocardial Infarction

    • A. D. Castaigne
    • A. M. Duval
    • Y. Louvard

    Section 3: Efficacy of Anisoylated Plasminogen Streptokinase Activator Complex: Evidence of Myocardial Function and Mortality Benefit 18 October 2012 Pages: 231 - 234

42. Discussion: Section 3

    • W. S. Hillis
    • Th. Meinertz

    Section 3: Efficacy of Anisoylated Plasminogen Streptokinase Activator Complex: Evidence of Myocardial Function and Mortality Benefit 18 October 2012 Pages: 235 - 236

43. Fibrinogen Concentration and Coronary Artery Reperfusion after Intravenous Anisoylated Plasminogen Streptokinase Activator Complex or Intracoronary Streptokinase Therapy

    • Victor J. Marder
    • Patricia A. Kinsella
    • M. Julianne Brown

    Section 4: Anisoylated Plasminogen Streptokinase Activator Complex and Haematological Parameters 18 October 2012 Pages: 237 - 241

44. Systemic Effects of Anisoylated Plasminogen Streptokinase Activator Complex and Streptokinase Therapy in Acute Myocardial Infarction

    • J. J. M. L. Hoffmann
    • J. J. R. M. Bonnier
    • M. Vijgen

    Section 4: Anisoylated Plasminogen Streptokinase: Activator Complex and Haematological Parameters 18 October 2012 Pages: 242 - 246

45. Haematological Effects of Anisoylated Plasminogen Streptokinase Activator Complex and Streptokinase in Patients with Acute Myocardial Infarction

    • J. -P. Monassier
    • M. Haussen

    Section 4: Anisoylated Plasminogen Streptokinase: Activator Complex and Haematological Parameters 18 October 2012 Pages: 247 - 252

46. Analysis of Coagulation and Fibrinolysis after Intravenous Anisoylated Plasminogen Streptokinase Activator Complex or Heparin in Patients with Acute Myocardial Infarction

    • J. Renkin
    • C. Col-De Beys
    • J. Col

    Section 4: Anisoylated Plasminogen Streptokinase: Activator Complex and Haematological Parameters 18 October 2012 Pages: 253 - 260

47. Anisoylated Plasminogen Streptokinase Activator Complex versus Placebo

    • D. G. Julian
    • L. S. Borthwick
    • W. S. Phillips

    Section 4: Anisoylated Plasminogen Streptokinase: Activator Complex and Haematological Parameters 18 October 2012 Pages: 261 - 267

48. Biological Study of Intravenous Anisoylated Plasminogen Streptokinase Activator Complex in Acute Myocardial Infarction

    • M. Samama
    • J. Conard
    • J. Acar

    Section 4: Anisoylated Plasminogen Streptokinase: Activator Complex and Haematological Parameters 18 October 2012 Pages: 268 - 274

49. Discussion

    • V. J. Marder
    • M. Samama

    Section 4: Anisoylated Plasminogen Streptokinase: Activator Complex and Haematological Parameters 18 October 2012 Pages: 275 - 275

50. Comparative Tolerance and Complications in a Multicentre Trial of Intracoronary Streptokinase and Intravenous Anisoylated Plasminogen Streptokinase Activator Complex in Acute Myocardial Infarction

    • Robert L. Rothbard

    Section 5: Safety and Tolerance Data 18 October 2012 Pages: 276 - 278